EP4149552A4 - Compositions et méthodes pour accroître l'efficacité d'un médicament - Google Patents

Compositions et méthodes pour accroître l'efficacité d'un médicament Download PDF

Info

Publication number: EP4149552A4
Authority: EP; European Patent Office
Prior art keywords: effectiveness; drug; compositions; increasing; methods
Prior art date: 2020-05-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP21803283.7A

Other languages

German (de)

English (en)

Other versions

EP4149552A1 (fr

Inventor

Sina Bavari

Simon NEWMAN

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tonix Pharma Ltd Ireland

Original Assignee

Healion Bio Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-05-15

Filing date

2021-05-14

Publication date

2024-06-19

2021-05-14 Application filed by Healion Bio Inc filed Critical Healion Bio Inc

2023-03-22 Publication of EP4149552A1 publication Critical patent/EP4149552A1/fr

2024-06-19 Publication of EP4149552A4 publication Critical patent/EP4149552A4/fr

Status Withdrawn legal-status Critical Current

Links

239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EP21803283.7A 2020-05-15 2021-05-14 Compositions et méthodes pour accroître l'efficacité d'un médicament Withdrawn EP4149552A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US202063025770P	2020-05-15	2020-05-15
PCT/US2021/032461 WO2021231872A1 (fr)	2020-05-15	2021-05-14	Compositions et méthodes pour accroître l'efficacité d'un médicament

Publications (2)

Publication Number	Publication Date
EP4149552A1 EP4149552A1 (fr)	2023-03-22
EP4149552A4 true EP4149552A4 (fr)	2024-06-19

Family

ID=78525057

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21803283.7A Withdrawn EP4149552A4 (fr)	2020-05-15	2021-05-14	Compositions et méthodes pour accroître l'efficacité d'un médicament

Country Status (5)

Country	Link
EP (1)	EP4149552A4 (fr)
JP (1)	JP2023526327A (fr)
CN (1)	CN116157152A (fr)
AU (1)	AU2021271806A1 (fr)
WO (1)	WO2021231872A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11857617B2 (en) *	2021-05-10	2024-01-02	Topelia Aust Limited (652 771 670)	Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment
AU2022306289A1 (en)	2021-07-09	2024-01-18	Aligos Therapeutics, Inc.	Anti-viral compounds
WO2023043816A1 (fr)	2021-09-17	2023-03-23	Aligos Therapeutics, Inc.	Composés antiviraux pour le traitement d'infections à coronavirus, picornavirus et norovirus
CN114957381B (zh) *	2021-10-22	2026-04-17	广州谷森制药有限公司	新型氘代氰基类化合物、其制备方法、组合物及应用
EP4452220A1 (fr) *	2021-12-23	2024-10-30	Subintro Limited	Nouvelles compositions antivirales comprenant de l'acide oléique
CN114409727A (zh) *	2021-12-28	2022-04-29	苏州康纯医药科技有限公司	一种抗冠状病毒的3clpro抑制剂的制备方法
WO2023132842A1 (fr) *	2022-01-10	2023-07-13	AiPharma Global Holdings LLC	Combinaison de médicaments pour traiter des infections microbiennes comprenant le coronavirus
CN120112285A (zh) *	2022-11-03	2025-06-06	上海科技大学	Aloxistatin在制备抗病毒感染的药物中的应用
CN116421608B (zh) *	2023-03-29	2025-08-08	中国疾病预防控制中心病毒病预防控制所	加利地韦在体外抑制狂犬病病毒中的应用
CN118090994B (zh) *	2024-04-26	2024-06-21	上海安谱实验科技股份有限公司	一种包含利托那韦和基质的稳定冻干剂、制备方法、试剂盒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021191875A1 (fr) *	2020-03-26	2021-09-30	Glaxosmithkline Intellectual Property Development Limited	Inhibiteurs de cathepsine pour la prévention ou le traitement d'infections virales
WO2021231570A1 (fr) *	2020-05-13	2021-11-18	The Regents Of The University Of Michigan	Cystéamine pour le traitement d'une infection par sras-cov-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6004933A (en) *	1997-04-25	1999-12-21	Cortech Inc.	Cysteine protease inhibitors
CA2850003C (fr) *	2011-09-27	2020-01-07	Kansas State University Research Foundation	Antiviraux a large spectre contre des proteases 3c ou 3c-associees du super-groupe des picornavirus-associes : picornavirus, calicivirus et coronavirus
WO2019032726A1 (fr) *	2017-08-09	2019-02-14	Cutanea Life Sciences, Inc.	Méthodes de traitement et de prévention d'infections virales

2021
- 2021-05-14 JP JP2022569505A patent/JP2023526327A/ja active Pending
- 2021-05-14 CN CN202180060848.1A patent/CN116157152A/zh active Pending
- 2021-05-14 AU AU2021271806A patent/AU2021271806A1/en not_active Abandoned
- 2021-05-14 EP EP21803283.7A patent/EP4149552A4/fr not_active Withdrawn
- 2021-05-14 WO PCT/US2021/032461 patent/WO2021231872A1/fr not_active Ceased

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021191875A1 (fr) *	2020-03-26	2021-09-30	Glaxosmithkline Intellectual Property Development Limited	Inhibiteurs de cathepsine pour la prévention ou le traitement d'infections virales
WO2021231570A1 (fr) *	2020-05-13	2021-11-18	The Regents Of The University Of Michigan	Cystéamine pour le traitement d'une infection par sras-cov-2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MANLI WANG ET AL: "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", CELL RESEARCH, 4 February 2020 (2020-02-04), Singapore, XP055672526, ISSN: 1001-0602, DOI: 10.1038/s41422-020-0282-0 *
NAIONAL INSTITUTES OF HEALTH: "Therapeutic Options Under Investigation \| Coronavirus Disease COVID-19", 21 April 2020 (2020-04-21), pages 1, XP093153428, Retrieved from the Internet <URL:https://web.archive.org/web/20200421163941/https://covid19treatmentguidelines.nih.gov/therapeutic-options-under-investigation/> *
See also references of WO2021231872A1 *

Also Published As

Publication number	Publication date
EP4149552A1 (fr)	2023-03-22
JP2023526327A (ja)	2023-06-21
WO2021231872A1 (fr)	2021-11-18
AU2021271806A1 (en)	2022-12-15
CN116157152A (zh)	2023-05-23

Legal Events

Date	Code	Title	Description
2021-11-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-02-17	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2023-02-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-03-22	17P	Request for examination filed	Effective date: 20221115
2023-03-22	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-08-23	DAV	Request for validation of the european patent (deleted)
2023-08-23	DAX	Request for extension of the european patent (deleted)
2023-12-01	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40091220 Country of ref document: HK
2024-05-15	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0041000000 Ipc: A61K0031495000
2024-06-19	A4	Supplementary search report drawn up and despatched	Effective date: 20240522
2024-06-19	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 31/14 20060101ALI20240515BHEP Ipc: A61P 31/12 20060101ALI20240515BHEP Ipc: A61K 45/06 20060101ALI20240515BHEP Ipc: A61K 31/4965 20060101ALI20240515BHEP Ipc: A61K 31/495 20060101AFI20240515BHEP
2024-07-31	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: TONIX PHARMA LIMITED
2025-04-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2025-05-14	18D	Application deemed to be withdrawn	Effective date: 20241212

Publication	Publication Date	Title
EP4149552A4 (fr)	2024-06-19	Compositions et méthodes pour accroître l'efficacité d'un médicament
EP4034253A4 (fr)	2024-02-07	Compositions et méthodes pour accroître l'efficacité d'immunothérapies et de vaccins
EP3924481A4 (fr)	2023-01-25	Compositions et méthodes de traitement d'hémoglobinopathies
EP3781705A4 (fr)	2022-01-26	Compositions et méthodes pour l'édition génique
EP4277616A4 (fr)	2024-12-25	Formulations d'agents pénétrants transdermiques pour l'administration de médicaments
MA52861A (fr)	2021-05-05	Méthodes et compositions pour le traitement de l'apnée du sommeil
EP3768242A4 (fr)	2021-12-08	Méthodes et compositions pour l'administration ciblée d'agents actifs et d'agents immunomodulateurs à des ganglions lymphatiques
EP3921420A4 (fr)	2022-11-16	Compositions d'administration de médicament pour l'administration oculaire d'agents thérapeutiques et leurs méthodes d'utilisation
EP3743091A4 (fr)	2021-12-15	Méthodes et compositions pour le traitement de troubles angiogéniques à l'aide d'agents anti-vegf
EP4121022A4 (fr)	2024-06-19	Compositions et méthodes pour le traitement et la prévention d'une infection à coronavirus
EP4297784A4 (fr)	2025-02-12	Compositions et méthodes d'administration thérapeutique
EP4337203A4 (fr)	2025-04-09	Inhibiteurs de l'interaction ménine-mll
EP3920898A4 (fr)	2022-11-09	Méthodes et compositions pour le traitement de l'apnée du sommeil
EP4058062A4 (fr)	2023-11-08	Compositions et méthodes pour l'immunothérapie
EP3810091A4 (fr)	2022-03-02	Méthodes et compositions pour le traitement de l'hypertension pulmonaire
MA52587A (fr)	2021-03-17	Composés d'azabenzimidazole et produit pharmaceutique
EP4114422A4 (fr)	2024-09-18	Compositions et méthodes pour le traitement d'infections bactériennes intracellulaires
EP3951290A4 (fr)	2022-05-25	Réfrigérateur et ensemble d'infusion pour réfrigérateur
EP3768301A4 (fr)	2022-06-08	Compositions et méthodes d'inhibition de fas
EP4073060A4 (fr)	2023-12-06	Inhibiteurs de l'histone déméthylase spécifique de la lysine pour le traitement de néoplasmes myéloprolifératifs
EP3876955A4 (fr)	2022-08-24	Méthodes et compositions pour déterminer la composition d'un microenvironnement tumoral
EP3946380A4 (fr)	2022-12-21	Compositions et méthodes pour l'immuno-cancérothérapie
MA53333A (fr)	2021-11-03	Formulations pharmaceutiques d'anticorps masqués
EP3740247A4 (fr)	2022-06-08	Compositions et méthodes pour inhiber l'expression de gys2
MA51869A (fr)	2020-12-23	Compositions et méthodes pour l'édition génique par ciblage du fibrinogène-alpha